$BDTX up 31% 🚀 🔹 Black Diamond Therapeutics ripping as oncology biotech momentum heats back up 📈 🔹 Company is focused on MasterKey therapies targeting genet

$BDTX up 31% 🚀 🔹 Black Diamond Therapeutics ripping as oncology biotech momentum heats back up 📈 🔹 Company is focused on MasterKey therapies targeting genetically defined cancers, including NSCLC 🧬 🔹 Traders watching silevertinib as a key pipeline driver with Phase 2 data potential in focus 💥…